1. Aristizabal S, Caldwell WL, Avila J. The relationship of time-dose fractionation factors to complications in the treatment of pituitary tumors by irradiation. Int.J.Rad.Oncol.Biol.Phys. 1977;2:667-673.
2. Atkinson AB, Allen IV, Gordon DS, et al. Progressive visual failure in acromegaly following external pituitary adenoma. Clin Endocrinol 1979;10:469-479.
3. Bloom B, Kramer S. Conventional Radiation Therapy in the Management of Acromegaly. In: McL.Black P.et al., editors. Secretory Tumors of the Pituitary Gland, 1st ed. Progress in Endocrine Research and Therapy, New York: Raven Press; 1984:179-190.
4. Forrest APM, Peebles Brown DA, Morris SR, Illingworth CFW. Pituitary radon implant for advanced cancer. The Lancet 1956;270:399-401.
5. Hammer HM. Optic Chiasmal Radionecrosis. Trans.ophthal.Soc.U.K. 1983;103:208-211.
6. Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. Radiother.Oncol. 1994;30:17-25.
7. Kline LB, Kim JY, Ceballos R. Radiation optic neuropathy. Ophthalmology 1985;92:1118-1126.
8. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinology and Metabolism 1998;83:2646-2652.
9. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int.J.Radiation Oncology Biol.Phys. 1994;30:755-764.
10. Speirs CJ, Reed PI, Morrison R, Joplin GF. The effectiveness of external beam radiotherapy for acromegaly is not affected by previous pituitary ablative treatments. Acta Endocrinol. 1990;122:559-565.
11. Wambersie, A. ICRU Report 62; prescribing, recording and reporting photon beam therapy (Supplement to ICRU 50); 1999.